John Maris Laboratory
New drugs are being identified for assessment in clinical trials that target specific genetic profiles in children with neuroblastoma.
Researchers are investigating how the genetic profiles of tumors from children with neuroblastoma are indicative of how aggressively they behave and are also working to identify potential avenues for targeted intervention.
Molecular profiling of tumors from patients with relapsed or refractory neuroblastoma may help determine more rational treatment options.
Investigators are examining the use of injectable alpha-emitting radionuclide MABG, a potent form of radiotherapy that specifically targets neuroblastoma cells.